Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Letrozole +/- Ribociclib in Advanced or Recurrent Endometrial Carcinoma
NCT03008408Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2017
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribociclib in endometrial carcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2017; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT03008408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008408.